Accord UK has launched Dutasteride 0.5mg Soft Capsules, following a patent expiry. Dutasteride 0.5mg Soft Capsules are indicated in the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) and reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH.

Pete Kelly, managing director of Accord UK said: “We remain committed to bringing cost competitive products to market at the earliest opportunity, with the launch of Dutasteride 0.5mg Soft Capsules being our latest day one patent expiry launch.”

ACCORD UK 0800 731 0370,


Brand insight: P3 June 2018

Recent product profiles from June's P3 magazine: women's health and child and infant health

Flarin gets TV support

The roll out of Flarin ibuprofen capsules is being supported with a national TV campaign